{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T09:54:14Z","timestamp":1792144454972,"version":"4.4.0"},"reference-count":150,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2018,3,29]],"date-time":"2018-03-29T00:00:00Z","timestamp":1522281600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["1066550"],"award-info":[{"award-number":["1066550"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001168","name":"Cancer Council Queensland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001168","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000923","name":"Australian Research Council","doi-asserted-by":"publisher","award":["DP 120103099"],"award-info":[{"award-number":["DP 120103099"]}],"id":[{"id":"10.13039\/501100000923","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"DOI":"10.3389\/fonc.2018.00092","type":"journal-article","created":{"date-parts":[[2018,3,29]],"date-time":"2018-03-29T00:22:59Z","timestamp":1522282979000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":625,"title":["Combination Therapy With Histone Deacetylase Inhibitors (HDACi) for the Treatment of Cancer: Achieving the Full Therapeutic Potential of HDACi"],"prefix":"10.3389","volume":"8","author":[{"given":"Amila","family":"Suraweera","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth J.","family":"O\u2019Byrne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek J.","family":"Richard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2018,3,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"3898","DOI":"10.3390\/molecules20033898","article-title":"Histone deacetylase inhibitors in clinical studies as templates for new anticancer agents","volume":"20","author":"Mottamal","year":"2015","journal-title":"Molecules"},{"key":"B2","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/2045-3701-4-45","article-title":"Epigenetic regulation in cancer progression","volume":"4","author":"Baxter","year":"2014","journal-title":"Cell Biosci"},{"key":"B3","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/carcin\/bgp220","article-title":"Epigenetics in cancer","volume":"31","author":"Sharma","year":"2010","journal-title":"Carcinogenesis"},{"key":"B4","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1158\/1055-9965.EPI-06-1069","article-title":"Non-Hodgkin lymphoma secondary to cancer chemotherapy","volume":"16","author":"Krishnan","year":"2007","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"B5","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.ctrv.2007.08.001","article-title":"Novel cytotoxic drugs: old challenges, new solutions","volume":"34","author":"Ismael","year":"2008","journal-title":"Cancer Treat Rev"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.2217\/fon-2016-0086","article-title":"Immune checkpoint inhibitors as first-line and salvage therapy for advanced non-small-cell lung cancer","volume":"12","author":"Decatris","year":"2016","journal-title":"Future Oncol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1111\/ajco.12698","article-title":"Immune checkpoint inhibitors: navigating a new paradigm of treatment toxicities","volume":"13","author":"Roberts","year":"2017","journal-title":"Asia Pac J Clin Oncol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1124\/mi.7.4.8","article-title":"Optimizing combination chemotherapy by controlling drug ratios","volume":"7","author":"Mayer","year":"2007","journal-title":"Mol Interv"},{"key":"B9","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","article-title":"Drug combination studies and their synergy quantification using the Chou-Talalay method","volume":"70","author":"Chou","year":"2010","journal-title":"Cancer Res"},{"key":"B10","doi-asserted-by":"publisher","first-page":"341","DOI":"10.2174\/156720105774370294","article-title":"The formulation of lipid-based nanotechnologies for the delivery of fixed dose anticancer drug combinations","volume":"2","author":"Ramsay","year":"2005","journal-title":"Curr Drug Deliv"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1016\/s1470-2045(16)30498-3","article-title":"Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study","volume":"17","author":"Langer","year":"2016","journal-title":"Lancet Oncol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/38664","article-title":"Histone acetylation in chromatin structure and transcription","volume":"389","author":"Grunstein","year":"1997","journal-title":"Nature"},{"key":"B13","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1038\/35106079","article-title":"Histone deacetylases and cancer: causes and therapies","volume":"1","author":"Marks","year":"2001","journal-title":"Nat Rev Cancer"},{"key":"B14","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.molonc.2007.01.001","article-title":"The role of histone deacetylases (HDACs) in human cancer","volume":"1","author":"Ropero","year":"2007","journal-title":"Mol Oncol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"5541","DOI":"10.1038\/sj.onc.1210620","article-title":"Histone deacetylase inhibitors: molecular mechanisms of action","volume":"26","author":"Xu","year":"2007","journal-title":"Oncogene"},{"key":"B16","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1126\/science.272.5260.408","article-title":"A mammalian histone deacetylase related to the yeast transcriptional regulator Rpd3p","volume":"272","author":"Taunton","year":"1996","journal-title":"Science"},{"key":"B17","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1038\/bjc.2013.21","article-title":"Histone deacetylase inhibitors as radiosensitisers: effects on DNA damage signalling and repair","volume":"108","author":"Groselj","year":"2013","journal-title":"Br J Cancer"},{"key":"B18","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1146\/annurev.biochem.73.011303.073651","article-title":"The Sir2 family of protein deacetylases","volume":"73","author":"Blander","year":"2004","journal-title":"Annu Rev Biochem"},{"key":"B19","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1038\/nrd2133","article-title":"Anticancer activities of histone deacetylase inhibitors","volume":"5","author":"Bolden","year":"2006","journal-title":"Nat Rev Drug Discov"},{"key":"B20","doi-asserted-by":"publisher","first-page":"a026831","DOI":"10.1101\/cshperspect.a026831","article-title":"HDACs and HDAC inhibitors in cancer development and therapy","volume":"6","author":"Li","year":"2016","journal-title":"Cold Spring Harb Perspect Med"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1593\/neo.08474","article-title":"Expression of class I histone deacetylases indicates poor prognosis in endometrioid subtypes of ovarian and endometrial carcinomas","volume":"10","author":"Weichert","year":"2008","journal-title":"Neoplasia"},{"key":"B22","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/s1470-2045(08)70004-4","article-title":"Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis","volume":"9","author":"Weichert","year":"2008","journal-title":"Lancet Oncol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1158\/1078-0432.Ccr-08-0684","article-title":"Histone deacetylase 8 in neuroblastoma tumorigenesis","volume":"15","author":"Oehme","year":"2009","journal-title":"Clin Cancer Res"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.4161\/15592294.2014.983367","article-title":"Dysregulated class I histone deacetylases are indicators of poor prognosis in multiple myeloma","volume":"9","author":"Mithraprabhu","year":"2014","journal-title":"Epigenetics"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.canlet.2012.09.018","article-title":"Combination therapy: histone deacetylase inhibitors and platinum-based chemotherapeutics for cancer","volume":"329","author":"Diyabalanage","year":"2013","journal-title":"Cancer Lett"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.3390\/ijms18071414","article-title":"Histone deacetylase inhibitors as anticancer drugs","volume":"18","author":"Eckschlager","year":"2017","journal-title":"Int J Mol Sci"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1634\/theoncologist.12-10-1247","article-title":"FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma","volume":"12","author":"Mann","year":"2007","journal-title":"Oncologist"},{"key":"B28","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1586\/era.10.88","article-title":"Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors","volume":"10","author":"Grant","year":"2010","journal-title":"Expert Rev Anticancer Ther"},{"key":"B29","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1177\/2040620715592567","article-title":"Belinostat in patients with refractory or relapsed peripheral T-cell lymphoma: a perspective review","volume":"6","author":"Sawas","year":"2015","journal-title":"Ther Adv Hematol"},{"key":"B30","first-page":"296","article-title":"Panobinostat (Farydak): a novel option for the treatment of relapsed or relapsed and refractory multiple myeloma","volume":"41","author":"Moore","year":"2016","journal-title":"P T"},{"key":"B31","doi-asserted-by":"publisher","first-page":"2934","DOI":"10.1038\/sj.onc.1207515","article-title":"Apoptosis defects and chemotherapy resistance: molecular interaction maps and networks","volume":"23","author":"Pommier","year":"2004","journal-title":"Oncogene"},{"key":"B32","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/S0891-5849(00)00313-0","article-title":"The role of the redox protein thioredoxin in cell growth and cancer","volume":"29","author":"Powis","year":"2000","journal-title":"Free Radic Biol Med"},{"key":"B33","first-page":"1129","article-title":"Increased expression of peroxiredoxin II confers resistance to cisplatin","volume":"21","author":"Chung","year":"2001","journal-title":"Anticancer Res"},{"key":"B34","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1021\/mp200329f","article-title":"Histone deacetylase inhibitors: emerging mechanisms of resistance","volume":"8","author":"Robey","year":"2011","journal-title":"Mol Pharm"},{"key":"B35","doi-asserted-by":"publisher","first-page":"7237","DOI":"10.1158\/1078-0432.Ccr-07-2114","article-title":"Mechanisms of resistance to histone deacetylase inhibitors and their therapeutic implications","volume":"13","author":"Fantin","year":"2007","journal-title":"Clin Cancer Res"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1002\/bies.201600070","article-title":"Histone deacetylase inhibitors for cancer therapy: an evolutionarily ancient resistance response may explain their limited success","volume":"38","author":"Halsall","year":"2016","journal-title":"Bioessays"},{"key":"B37","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1038\/sj.bjc.6604557","article-title":"Will histone deacetylase inhibitors require combination with other agents to fulfil their therapeutic potential?","volume":"99","author":"Nolan","year":"2008","journal-title":"Br J Cancer"},{"key":"B38","doi-asserted-by":"publisher","first-page":"777","DOI":"10.4161\/cc.3.6.927","article-title":"Histone-deacetylase inhibitors for the treatment of cancer","volume":"3","author":"Lindemann","year":"2004","journal-title":"Cell Cycle"},{"key":"B39","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1002\/jcp.25053","article-title":"Error-prone repair of DNA double-strand breaks","volume":"231","author":"Rodgers","year":"2016","journal-title":"J Cell Physiol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1038\/85798","article-title":"DNA double-strand breaks: signaling, repair and the cancer connection","volume":"27","author":"Khanna","year":"2001","journal-title":"Nat Genet"},{"key":"B41","doi-asserted-by":"publisher","first-page":"3683","DOI":"10.1093\/nar\/gkh703","article-title":"Conservative homologous recombination preferentially repairs DNA double-strand breaks in the S phase of the cell cycle in human cells","volume":"32","author":"Saleh-Gohari","year":"2004","journal-title":"Nucleic Acids Res"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1038\/sj.cdd.4400874","article-title":"ATM, a central controller of cellular responses to DNA damage","volume":"8","author":"Khanna","year":"2001","journal-title":"Cell Death Differ"},{"key":"B43","doi-asserted-by":"publisher","first-page":"14639","DOI":"10.1073\/pnas.1008522107","article-title":"Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair","volume":"107","author":"Lee","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B44","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1038\/onc.2011.267","article-title":"Endogenous modulators and pharmacological inhibitors of histone deacetylases in cancer therapy","volume":"31","author":"Spiegel","year":"2012","journal-title":"Oncogene"},{"key":"B45","doi-asserted-by":"publisher","first-page":"5057","DOI":"10.1073\/pnas.0830918100","article-title":"Evidence for a lack of DNA double-strand break repair in human cells exposed to very low x-ray doses","volume":"100","author":"Rothkamm","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B46","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1158\/1535-7163.MCT-12-1242","article-title":"Histone deacetylase regulation of ATM-mediated DNA damage signaling","volume":"12","author":"Thurn","year":"2013","journal-title":"Mol Cancer Ther"},{"key":"B47","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1146\/annurev.immunol.15.1.177","article-title":"The genetic defect in ataxia-telangiectasia","volume":"15","author":"Lavin","year":"1997","journal-title":"Annu Rev Immunol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.canlet.2008.06.005","article-title":"Histone deacetylase inhibitors and genomic instability","volume":"274","author":"Eot-Houllier","year":"2009","journal-title":"Cancer Lett"},{"key":"B49","doi-asserted-by":"publisher","first-page":"31127","DOI":"10.1074\/jbc.274.44.31127","article-title":"Sensing of ionizing radiation-induced DNA damage by ATM through interaction with histone deacetylase","volume":"274","author":"Kim","year":"1999","journal-title":"J Biol Chem"},{"key":"B50","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1158\/1535-7163.MCT-08-0985","article-title":"HDAC2 regulates chromatin plasticity and enhances DNA vulnerability","volume":"8","author":"Marchion","year":"2009","journal-title":"Mol Cancer Ther"},{"key":"B51","doi-asserted-by":"publisher","first-page":"e1053594","DOI":"10.1080\/23723556.2015.1053594","article-title":"Trial watch \u2013 inhibiting PARP enzymes for anticancer therapy","volume":"3","author":"Sistigu","year":"2016","journal-title":"Mol Cell Oncol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"4257","DOI":"10.1158\/1078-0432.CCR-15-0887","article-title":"FDA approval summary: olaparib monotherapy in patients with deleterious germline BRCA-mutated advanced ovarian cancer treated with three or more lines of chemotherapy","volume":"21","author":"Kim","year":"2015","journal-title":"Clin Cancer Res"},{"key":"B53","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1056\/NEJMoa1706450","article-title":"Olaparib for metastatic breast cancer in patients with a germline BRCA mutation","volume":"377","author":"Robson","year":"2017","journal-title":"N Engl J Med"},{"key":"B54","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1002\/med.20056","article-title":"Targeting histone deacetylase in cancer therapy","volume":"26","author":"Lin","year":"2006","journal-title":"Med Res Rev"},{"key":"B55","doi-asserted-by":"publisher","first-page":"5318","DOI":"10.1158\/0008-5472.CAN-06-3996","article-title":"Histone deacetylase inhibitors sensitize prostate cancer cells to agents that produce DNA double-strand breaks by targeting Ku70 acetylation","volume":"67","author":"Chen","year":"2007","journal-title":"Cancer Res"},{"key":"B56","doi-asserted-by":"publisher","first-page":"3885","DOI":"10.1038\/sj.onc.1209417","article-title":"Modulation of cellular radiation responses by histone deacetylase inhibitors","volume":"25","author":"Karagiannis","year":"2006","journal-title":"Oncogene"},{"key":"B57","doi-asserted-by":"publisher","first-page":"263","DOI":"10.2217\/fon.11.2","article-title":"Rational therapeutic combinations with histone deacetylase inhibitors for the treatment of cancer","volume":"7","author":"Thurn","year":"2011","journal-title":"Future Oncol"},{"key":"B58","doi-asserted-by":"publisher","first-page":"2735","DOI":"10.1111\/j.1582-4934.2011.01296.x","article-title":"Grand rounds at the National Institutes of Health: HDAC inhibitors as radiation modifiers, from bench to clinic","volume":"15","author":"Shabason","year":"2011","journal-title":"J Cell Mol Med"},{"key":"B59","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1507\/endocrj.K08E-016","article-title":"Successful treatment of anaplastic thyroid carcinoma with a combination of oral valproic acid, chemotherapy, radiation and surgery","volume":"56","author":"Noguchi","year":"2009","journal-title":"Endocr J"},{"key":"B60","doi-asserted-by":"publisher","first-page":"601","DOI":"10.2217\/fon.09.36","article-title":"Panobinostat (LBH589): a potent pan-deacetylase inhibitor with promising activity against hematologic and solid tumors","volume":"5","author":"Prince","year":"2009","journal-title":"Future Oncol"},{"key":"B61","doi-asserted-by":"publisher","first-page":"2132","DOI":"10.1002\/cncr.22652","article-title":"Epigenetic combination therapy as a tumor-selective treatment approach for hepatocellular carcinoma","volume":"109","author":"Venturelli","year":"2007","journal-title":"Cancer"},{"key":"B62","doi-asserted-by":"publisher","first-page":"e74253","DOI":"10.1371\/journal.pone.0074253","article-title":"Combination therapy with the histone deacetylase inhibitor LBH589 and radiation is an effective regimen for prostate cancer cells","volume":"8","author":"Xiao","year":"2013","journal-title":"PLoS One"},{"key":"B63","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1146\/annurev-biochem-061809-100002","article-title":"New mechanistic and functional insights into DNA topoisomerases","volume":"82","author":"Chen","year":"2013","journal-title":"Annu Rev Biochem"},{"key":"B64","doi-asserted-by":"publisher","first-page":"8467","DOI":"10.1158\/1078-0432.CCR-05-1073","article-title":"Synergistic interaction between histone deacetylase and topoisomerase II inhibitors is mediated through topoisomerase IIbeta","volume":"11","author":"Marchion","year":"2005","journal-title":"Clin Cancer Res"},{"key":"B65","doi-asserted-by":"publisher","first-page":"3472","DOI":"10.1158\/1078-0432.CCR-08-2714","article-title":"Combining PCI-24781, a novel histone deacetylase inhibitor, with chemotherapy for the treatment of soft tissue sarcoma","volume":"15","author":"Lopez","year":"2009","journal-title":"Clin Cancer Res"},{"key":"B66","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s11060-007-9402-7","article-title":"Valproic acid induces p21 and topoisomerase-II (alpha\/beta) expression and synergistically enhances etoposide cytotoxicity in human glioblastoma cell lines","volume":"85","author":"Das","year":"2007","journal-title":"J Neurooncol"},{"key":"B67","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.1038\/bjc.2011.156","article-title":"A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer","volume":"104","author":"Munster","year":"2011","journal-title":"Br J Cancer"},{"key":"B68","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1002\/jcb.20045","article-title":"Sequence-specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acid","volume":"92","author":"Marchion","year":"2004","journal-title":"J Cell Biochem"},{"key":"B69","doi-asserted-by":"publisher","first-page":"3815","DOI":"10.1158\/0008-5472.can-04-2478","article-title":"Valproic acid alters chromatin structure by regulation of chromatin modulation proteins","volume":"65","author":"Marchion","year":"2005","journal-title":"Cancer Res"},{"key":"B70","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1200\/JCO.2006.08.6165","article-title":"Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational study","volume":"25","author":"Munster","year":"2007","journal-title":"J Clin Oncol"},{"key":"B71","doi-asserted-by":"publisher","first-page":"2488","DOI":"10.1158\/1078-0432.CCR-08-1930","article-title":"Clinical and biological effects of valproic acid as a histone deacetylase inhibitor on tumor and surrogate tissues: phase I\/II trial of valproic acid and epirubicin\/FEC","volume":"15","author":"Munster","year":"2009","journal-title":"Clin Cancer Res"},{"key":"B72","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1038\/sj.bjc.6605293","article-title":"Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker","volume":"101","author":"Munster","year":"2009","journal-title":"Br J Cancer"},{"key":"B73","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/S0305-7372(79)80057-2","article-title":"Cisplatin (cis-diamminedichloroplatinum II)","volume":"6","author":"Prestayko","year":"1979","journal-title":"Cancer Treat Rev"},{"key":"B74","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.jinorgbio.2016.06.021","article-title":"Anticancer metal drugs and immunogenic cell death","volume":"165","author":"Terenzi","year":"2016","journal-title":"J Inorg Biochem"},{"key":"B75","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1038\/onc.2011.384","article-title":"Molecular mechanisms of cisplatin resistance","volume":"31","author":"Galluzzi","year":"2012","journal-title":"Oncogene"},{"key":"B76","doi-asserted-by":"publisher","first-page":"201367","DOI":"10.4061\/2010\/201367","article-title":"Cellular responses to cisplatin-induced DNA damage","volume":"2010","author":"Basu","year":"2010","journal-title":"J Nucleic Acids"},{"key":"B77","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1016\/j.bcp.2007.03.009","article-title":"Enhancement of cisplatin induced apoptosis by suberoylanilide hydroxamic acid in human oral squamous cell carcinoma cell lines","volume":"73","author":"Shen","year":"2007","journal-title":"Biochem Pharmacol"},{"key":"B78","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1016\/j.juro.2010.10.034","article-title":"The histone deacetylase inhibitor trichostatin A synergistically resensitizes a cisplatin resistant human bladder cancer cell line","volume":"185","author":"Yoon","year":"2011","journal-title":"J Urol"},{"key":"B79","doi-asserted-by":"publisher","first-page":"185","DOI":"10.4161\/cbt.6.2.3578","article-title":"Valproic acid induces apoptosis, p16INK4Aupregulation and sensitization to chemotherapy in human melanoma cells","volume":"6","author":"Valentini","year":"2014","journal-title":"Cancer Biol Ther"},{"key":"B80","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/0305-7372(85)90015-5","article-title":"Preclinical studies identifying carboplatin as a viable cisplatin alternative","volume":"12","author":"Harrap","year":"1985","journal-title":"Cancer Treat Rev"},{"key":"B81","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1038\/sj.bjc.6605726","article-title":"A phase I study of the safety and pharmacokinetics of the histone deacetylase inhibitor belinostat administered in combination with carboplatin and\/or paclitaxel in patients with solid tumours","volume":"103","author":"Lassen","year":"2010","journal-title":"Br J Cancer"},{"key":"B82","doi-asserted-by":"publisher","first-page":"3605","DOI":"10.1158\/1078-0432.CCR-07-0162","article-title":"Phase I and pharmacokinetic study of vorinostat, a histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignancies","volume":"13","author":"Ramalingam","year":"2007","journal-title":"Clin Cancer Res"},{"key":"B83","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1097\/CCO.0b013e3283127095","article-title":"Histone deacetylase inhibitors in cancer therapy","volume":"20","author":"Lee","year":"2008","journal-title":"Curr Opin Oncol"},{"key":"B84","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1200\/JCO.2009.24.9094","article-title":"Carboplatin and paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung cancer","volume":"28","author":"Ramalingam","year":"2010","journal-title":"J Clin Oncol"},{"key":"B85","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.lungcan.2011.02.019","article-title":"Expression of histone deacetylase 1 correlates with a poor prognosis in patients with adenocarcinoma of the lung","volume":"74","author":"Minamiya","year":"2011","journal-title":"Lung Cancer"},{"key":"B86","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.molcel.2012.08.003","article-title":"Failure of amino acid homeostasis causes cell death following proteasome inhibition","volume":"48","author":"Suraweera","year":"2012","journal-title":"Mol Cell"},{"key":"B87","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1146\/annurev.biochem.67.1.425","article-title":"The ubiquitin system","volume":"67","author":"Hershko","year":"1998","journal-title":"Annu Rev Biochem"},{"key":"B88","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1146\/annurev.biochem.78.081507.101607","article-title":"Recognition and processing of ubiquitin-protein conjugates by the proteasome","volume":"78","author":"Finley","year":"2009","journal-title":"Annu Rev Biochem"},{"key":"B89","first-page":"4996","article-title":"Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model","volume":"62","author":"LeBlanc","year":"2002","journal-title":"Cancer Res"},{"key":"B90","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1042\/bst0350012","article-title":"Functions of the proteasome: from protein degradation and immune surveillance to cancer therapy","volume":"35","author":"Goldberg","year":"2007","journal-title":"Biochem Soc Trans"},{"key":"B91","doi-asserted-by":"publisher","first-page":"271","DOI":"10.2147\/tcrm.2006.2.3.271","article-title":"Bortezomib (velcadetrade mark) in the treatment of multiple myeloma","volume":"2","author":"Field-Smith","year":"2006","journal-title":"Ther Clin Risk Manag"},{"key":"B92","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1080\/10428190701817258","article-title":"Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma","volume":"49","author":"Richardson","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"B93","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1002\/cncr.25584","article-title":"Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myeloma","volume":"117","author":"Niesvizky","year":"2011","journal-title":"Cancer"},{"key":"B94","doi-asserted-by":"publisher","first-page":"8567","DOI":"10.1073\/pnas.0503221102","article-title":"Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma","volume":"102","author":"Hideshima","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B95","doi-asserted-by":"publisher","first-page":"3839","DOI":"10.1158\/1078-0432.ccr-03-0561","article-title":"Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors","volume":"10","author":"Pei","year":"2004","journal-title":"Clin Cancer Res"},{"key":"B96","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1111\/j.1600-0609.2009.01384.x","article-title":"Vorinostat enhances the antimyeloma effects of melphalan and bortezomib","volume":"84","author":"Campbell","year":"2010","journal-title":"Eur J Haematol"},{"key":"B97","doi-asserted-by":"publisher","first-page":"794","DOI":"10.3324\/haematol.2009.015495","article-title":"In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma","volume":"95","author":"Ocio","year":"2010","journal-title":"Haematologica"},{"key":"B98","doi-asserted-by":"publisher","first-page":"3441","DOI":"10.1182\/blood-2006-04-016055","article-title":"Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells","volume":"108","author":"Catley","year":"2006","journal-title":"Blood"},{"key":"B99","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.1158\/1535-7163.MCT-11-0433","article-title":"Mechanism of action of proteasome inhibitors and deacetylase inhibitors and the biological basis of synergy in multiple myeloma","volume":"10","author":"Hideshima","year":"2011","journal-title":"Mol Cancer Ther"},{"key":"B100","doi-asserted-by":"publisher","first-page":"2950","DOI":"10.1002\/ijc.28924","article-title":"Combination of proteasome and class I HDAC inhibitors induces apoptosis of NPC cells through an HDAC6-independent ER stress-induced mechanism","volume":"135","author":"Hui","year":"2014","journal-title":"Int J Cancer"},{"key":"B101","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1111\/j.1365-2141.2010.08342.x","article-title":"The class-I HDAC inhibitor MGCD0103 induces apoptosis in Hodgkin lymphoma cell lines and synergizes with proteasome inhibitors by an HDAC6-independent mechanism","volume":"151","author":"Buglio","year":"2010","journal-title":"Br J Haematol"},{"key":"B102","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.3892\/ol.2017.5585","article-title":"Proteasome inhibitors in glioblastoma","volume":"13","author":"Huang","year":"2017","journal-title":"Oncol Lett"},{"key":"B103","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1182\/blood-2012-10-459883","article-title":"Carfilzomib","volume":"121","author":"Kortuem","year":"2013","journal-title":"Blood"},{"key":"B104","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.drup.2014.12.001","article-title":"Molecular basis of resistance to proteasome inhibitors in hematological malignancies","volume":"18","author":"Niewerth","year":"2015","journal-title":"Drug Resist Updat"},{"key":"B105","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1002\/1097-0142(20011101)92:9<2247::AID-CNCR1570>3.0.CO;2-Y","article-title":"Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma","volume":"92","author":"Bonneterre","year":"2001","journal-title":"Cancer"},{"key":"B106","first-page":"5718","article-title":"Androgen receptor expression in androgen-independent prostate cancer is associated with increased expression of androgen-regulated genes","volume":"58","author":"Gregory","year":"1998","journal-title":"Cancer Res"},{"key":"B107","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s10549-005-6001-1","article-title":"Quantitation of HDAC1 mRNA expression in invasive carcinoma of the breast*","volume":"94","author":"Zhang","year":"2005","journal-title":"Breast Cancer Res Treat"},{"key":"B108","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1038\/sj.bjc.6604199","article-title":"Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy","volume":"98","author":"Weichert","year":"2008","journal-title":"Br J Cancer"},{"key":"B109","doi-asserted-by":"publisher","first-page":"7138","DOI":"10.1158\/1078-0432.CCR-08-0122","article-title":"A phase II trial of vorinostat (suberoylanilide hydroxamic acid) in metastatic breast cancer: a California Cancer Consortium study","volume":"14","author":"Luu","year":"2008","journal-title":"Clin Cancer Res"},{"key":"B110","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s00280-010-1289-x","article-title":"A phase I study of oral panobinostat alone and in combination with docetaxel in patients with castration-resistant prostate cancer","volume":"66","author":"Rathkopf","year":"2010","journal-title":"Cancer Chemother Pharmacol"},{"key":"B111","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1093\/annonc\/mdp270","article-title":"Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC)","volume":"21","author":"Molife","year":"2010","journal-title":"Ann Oncol"},{"key":"B112","doi-asserted-by":"publisher","first-page":"5541","DOI":"10.1002\/cncr.24597","article-title":"Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute trial 6862): trial results and interleukin-6 analysis: a study by the department of defense prostate cancer clinical trial consortium and University of Chicago phase 2 consortium","volume":"115","author":"Bradley","year":"2009","journal-title":"Cancer"},{"key":"B113","doi-asserted-by":"publisher","first-page":"2774","DOI":"10.1002\/ijc.23885","article-title":"Defining the molecular action of HDAC inhibitors and synergism with androgen deprivation in ERG-positive prostate cancer","volume":"123","author":"Bjorkman","year":"2008","journal-title":"Int J Cancer"},{"key":"B114","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1002\/pros.21187","article-title":"An in vitro model for preclinical testing of endocrine therapy combinations for prostate cancer","volume":"70","author":"Pfeiffer","year":"2010","journal-title":"Prostate"},{"key":"B115","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1158\/1535-7163.MCT-06-0144","article-title":"Suberoylanilide hydroxamic acid (vorinostat) represses androgen receptor expression and acts synergistically with an androgen receptor antagonist to inhibit prostate cancer cell proliferation","volume":"6","author":"Marrocco","year":"2007","journal-title":"Mol Cancer Ther"},{"key":"B116","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1177\/1756287215597637","article-title":"Histone deacetylase inhibitors in castration-resistant prostate cancer: molecular mechanism of action and recent clinical trials","volume":"7","author":"Kaushik","year":"2015","journal-title":"Ther Adv Urol"},{"key":"B117","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1586\/ecp.09.44","article-title":"Finding the place of histone deacetylase inhibitors in prostate cancer therapy","volume":"2","author":"Marrocco-Tallarigo","year":"2009","journal-title":"Expert Rev Clin Pharmacol"},{"key":"B118","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1248\/bpb.34.1774","article-title":"Receptor tyrosine kinases and targeted cancer therapeutics","volume":"34","author":"Takeuchi","year":"2011","journal-title":"Biol Pharm Bull"},{"key":"B119","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1124\/jpet.105.084145","article-title":"Role of tyrosine kinase inhibitors in cancer therapy","volume":"315","author":"Arora","year":"2005","journal-title":"J Pharmacol Exp Ther"},{"key":"B120","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1159\/000279388","article-title":"EGFR signaling and drug discovery","volume":"77","author":"Lurje","year":"2009","journal-title":"Oncology"},{"key":"B121","doi-asserted-by":"publisher","first-page":"16934","DOI":"10.1074\/jbc.M500403200","article-title":"Cyclin D1 inhibits peroxisome proliferator-activated receptor gamma-mediated adipogenesis through histone deacetylase recruitment","volume":"280","author":"Fu","year":"2005","journal-title":"J Biol Chem"},{"key":"B122","doi-asserted-by":"publisher","first-page":"5385","DOI":"10.1158\/1078-0432.CCR-08-0469","article-title":"Vorinostat and sorafenib synergistically kill tumor cells via FLIP suppression and CD95 activation","volume":"14","author":"Zhang","year":"2008","journal-title":"Clin Cancer Res"},{"key":"B123","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1200\/JCO.2003.10.038","article-title":"Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (the IDEAL 1 trial) [corrected]","volume":"21","author":"Fukuoka","year":"2003","journal-title":"J Clin Oncol"},{"key":"B124","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1093\/annonc\/mdn703","article-title":"ErbB-3 expression is associated with E-cadherin and their coexpression restores response to gefitinib in non-small-cell lung cancer (NSCLC)","volume":"20","author":"Witta","year":"2009","journal-title":"Ann Oncol"},{"key":"B125","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1634\/theoncologist.2012-0465","article-title":"Concise drug review: azacitidine and decitabine","volume":"18","author":"Derissen","year":"2013","journal-title":"Oncologist"},{"key":"B126","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.currproblcancer.2008.08.002","article-title":"DNA methylation: its role in cancer development and therapy","volume":"32","author":"Kurkjian","year":"2008","journal-title":"Curr Probl Cancer"},{"key":"B127","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/j.leukres.2004.11.022","article-title":"Antileukemia activity of the combination of 5-aza-2\u2019-deoxycytidine with valproic acid","volume":"29","author":"Yang","year":"2005","journal-title":"Leuk Res"},{"key":"B128","doi-asserted-by":"publisher","first-page":"3271","DOI":"10.1182\/blood-2006-03-009142","article-title":"Phase 1\/2 study of the combination of 5-aza-2\u2019-deoxycytidine with valproic acid in patients with leukemia","volume":"108","author":"Garcia-Manero","year":"2006","journal-title":"Blood"},{"key":"B129","doi-asserted-by":"publisher","first-page":"3906","DOI":"10.1200\/JCO.2005.07.450","article-title":"Pharmacokinetics of 5-azacitidine administered with phenylbutyrate in patients with refractory solid tumors or hematologic malignancies","volume":"23","author":"Rudek","year":"2005","journal-title":"J Clin Oncol"},{"key":"B130","doi-asserted-by":"publisher","first-page":"6361","DOI":"10.1158\/0008-5472.CAN-06-0080","article-title":"Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms","volume":"66","author":"Gore","year":"2006","journal-title":"Cancer Res"},{"key":"B131","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s40425-015-0059-z","article-title":"The therapeutic promise of disrupting the PD-1\/PD-L1 immune checkpoint in cancer: unleashing the CD8 T cell mediated anti-tumor activity results in significant, unprecedented clinical efficacy in various solid tumors","volume":"3","author":"Romano","year":"2015","journal-title":"J Immunother Cancer"},{"key":"B132","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.cell.2015.03.030","article-title":"Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential","volume":"161","author":"Sharma","year":"2015","journal-title":"Cell"},{"key":"B133","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s13148-017-0358-y","article-title":"Epi-drugs in combination with immunotherapy: a new avenue to improve anticancer efficacy","volume":"9","author":"Mazzone","year":"2017","journal-title":"Clin Epigenetics"},{"key":"B134","doi-asserted-by":"publisher","first-page":"415","DOI":"10.2217\/epi.15.118","article-title":"Histone deacetylase inhibitors as immunomodulators in cancer therapeutics","volume":"8","author":"Shen","year":"2016","journal-title":"Epigenomics"},{"key":"B135","doi-asserted-by":"publisher","first-page":"83155","DOI":"10.18632\/oncotarget.17950","article-title":"HDAC inhibitors enhance the immunotherapy response of melanoma cells","volume":"8","author":"Booth","year":"2017","journal-title":"Oncotarget"},{"key":"B136","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1158\/2326-6066.Cir-15-0077-t","article-title":"HDAC inhibition upregulates PD-1 ligands in melanoma and augments immunotherapy with PD-1 blockade","volume":"3","author":"Woods","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"B137","doi-asserted-by":"publisher","first-page":"5960","DOI":"10.1038\/onc.2015.46","article-title":"Histone deacetylase inhibitors prevent activation-induced cell death and promote anti-tumor immunity","volume":"34","author":"Cao","year":"2015","journal-title":"Oncogene"},{"key":"B138","doi-asserted-by":"publisher","first-page":"11774","DOI":"10.1073\/pnas.1410626111","article-title":"Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells","volume":"111","author":"Kim","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B139","doi-asserted-by":"publisher","first-page":"5187","DOI":"10.1158\/1078-0432.Ccr-17-0741","article-title":"Entinostat neutralizes myeloid-derived suppressor cells and enhances the antitumor effect of PD-1 inhibition in murine models of lung and renal cell carcinoma","volume":"23","author":"Orillion","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B140","doi-asserted-by":"publisher","first-page":"e1219008","DOI":"10.1080\/2162402X.2016.1219008","article-title":"The interplay of epigenetic therapy and immunity in locally recurrent or metastatic estrogen receptor-positive breast cancer: correlative analysis of ENCORE 301, a randomized, placebo-controlled phase II trial of exemestane with or without entinostat","volume":"5","author":"Tomita","year":"2016","journal-title":"Oncoimmunology"},{"key":"B141","doi-asserted-by":"publisher","first-page":"7390","DOI":"10.18632\/oncotarget.7180","article-title":"Inhibitors of histone deacetylase 1 reverse the immune evasion phenotype to enhance T-cell mediated lysis of prostate and breast carcinoma cells","volume":"7","author":"Gameiro","year":"2016","journal-title":"Oncotarget"},{"key":"B142","doi-asserted-by":"publisher","first-page":"7199","DOI":"10.1158\/1078-0432.Ccr-17-1178","article-title":"Immunomodulation by entinostat in renal cell carcinoma patients receiving high-dose interleukin 2: a multicenter, single-arm, phase I\/II trial (NCI-CTEP#7870)","volume":"23","author":"Pili","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B143","doi-asserted-by":"publisher","first-page":"3997","DOI":"10.1158\/1078-0432.CCR-05-2689","article-title":"Cardiotoxicity of histone deacetylase inhibitor depsipeptide in patients with metastatic neuroendocrine tumors","volume":"12","author":"Shah","year":"2006","journal-title":"Clin Cancer Res"},{"key":"B144","doi-asserted-by":"publisher","first-page":"5459","DOI":"10.1200\/JCO.2009.22.1291","article-title":"Histone deacetylase inhibitors in cancer therapy","volume":"27","author":"Lane","year":"2009","journal-title":"J Clin Oncol"},{"key":"B145","doi-asserted-by":"publisher","first-page":"505","DOI":"10.4155\/fmc.12.3","article-title":"Targeted cancer therapy: giving histone deacetylase inhibitors all they need to succeed","volume":"4","author":"Gryder","year":"2012","journal-title":"Future Med Chem"},{"key":"B146","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/1476-4598-7-70","article-title":"Differential effects of class I isoform histone deacetylase depletion and enzymatic inhibition by belinostat or valproic acid in HeLa cells","volume":"7","author":"Dejligbjerg","year":"2008","journal-title":"Mol Cancer"},{"key":"B147","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1158\/1535-7163.MCT-07-2140","article-title":"Antitumor activity of histone deacetylase inhibitors in non-small cell lung cancer cells: development of a molecular predictive model","volume":"7","author":"Miyanaga","year":"2008","journal-title":"Mol Cancer Ther"},{"key":"B148","doi-asserted-by":"publisher","first-page":"3785","DOI":"10.1158\/0008-5472.CAN-07-6091","article-title":"Constitutive activation of signal transducers and activators of transcription predicts vorinostat resistance in cutaneous T-cell lymphoma","volume":"68","author":"Fantin","year":"2008","journal-title":"Cancer Res"},{"key":"B149","doi-asserted-by":"publisher","first-page":"86","DOI":"10.3389\/fonc.2014.00086","article-title":"Chemotherapeutic compounds targeting the DNA double-strand break repair pathways: the good, the bad, and the promising","volume":"4","author":"Jekimovs","year":"2014","journal-title":"Front Oncol"},{"key":"B150","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s13148-010-0012-4","article-title":"Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy","volume":"1","author":"Wagner","year":"2010","journal-title":"Clin Epigenetics"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fonc.2018.00092\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,3,29]],"date-time":"2018-03-29T00:23:05Z","timestamp":1522282985000},"score":1,"resource":{"primary":{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fonc.2018.00092\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,29]]},"references-count":150,"alternative-id":["10.3389\/fonc.2018.00092"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2018.00092","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,29]]},"article-number":"92"}}